Articles

Dr. Chris Chen, CEO of WuXi Biologics, discusses the evolving contract development and manufacturing organization landscape in this contributed article.
Nov. 17, 2026
Staffing and recruiting firm Vector Talent sees oligonucleotides “breaking out” of rare disease, and GLP-1s still driving most new fill-finish demand next year.
Nov. 16, 2026
The new injectable device manufacturing facility in Lehigh Valley will produce retatrutide, Lilly’s investigational once-weekly triple hormone receptor agonist.
Nov. 13, 2026
Sponsored
Optimizing pump performance, process control and efficiency from bench to production
Nov. 12, 2026
A little more than a year after taking the helm, Emmanuel Ligner contends the provider of products and services to the life sciences industry is positioned for growth.
Nov. 12, 2026
Uneven market recovery and differing customer priorities are pushing CDMOs to rethink how they demonstrate value and deliver on pharma’s expectations, finds Simon-Kucher.
Nov. 11, 2026
Continuous flow chemistry and AI-driven process control in active pharmaceutical ingredient production could reduce reliance on centralized manufacturing.
Nov. 10, 2026
The CRDMO’s delisting by the U.S. Department of Defense complies with a recent U.S. District Court of Columbia order granting WuXi AppTec’s motion for preliminary injunction.
Nov. 9, 2026
With Lonza’s creation of arguably the largest biologics CDMO network in the U.S., Samsung’s limited beachhead in America won’t be enough to compete.
Nov. 9, 2026

Looking for Something?